MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential

Leukemia is known as a progressive malignant disease, which destroys the blood‐forming organs and results in adverse effects on the proliferation and development of leukocytes and their precursors in the blood and bone marrow. There are four main classes of leukemia including acute leukemia, chronic...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of cellular physiology Vol. 234; no. 6; pp. 8465 - 8486
Main Authors:	Mardani, Rajab, Jafari Najaf Abadi, Mohammad Hassan, Motieian, Mahsa, Taghizadeh‐Boroujeni, Sima, Bayat, Amir, Farsinezhad, Alireza, Gheibi Hayat, Seyed Mohammad, Motieian, Mahtab, Pourghadamyari, Hossein
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-06-2019
Subjects:	biomarker Biomarkers Blood Bone marrow Chemotherapy Deregulation Diagnostic systems Epigenesis, Genetic - genetics exosome Genes, Tumor Suppressor Hemopoiesis Humans Leukemia Leukemia - genetics Leukemia - pathology Leukemia - therapy Leukocytes Lymphatic leukemia microRNA MicroRNAs - genetics miRNA Myeloid leukemia Non-coding RNA oncogene Oncogenes Oncogenes - genetics Organs Patients Regulators Ribonucleic acid RNA Suppressors Therapeutic applications therapy tumor suppressor Tumor suppressor genes Tumors leukemia therapy microRNA tumor suppressor biomarker oncogene exosome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Leukemia is known as a progressive malignant disease, which destroys the blood‐forming organs and results in adverse effects on the proliferation and development of leukocytes and their precursors in the blood and bone marrow. There are four main classes of leukemia including acute leukemia, chronic leukemia, myelogenous leukemia, and lymphocytic leukemia. Given that a variety of internal and external factors could be associated with the initiation and progression of different types of leukemia. One of the important factors is epigenetic regulators such as microRNAs (miRNAs) and long noncoding RNAs (ncRNA). MiRNAs are short ncRNAs which act as tumor suppressor (i.e., miR‐15, miR‐16, let‐7, and miR‐127) or oncogene (i.e., miR‐155, miR‐17‐92, miR‐21, miR‐125b, miR‐93, miR‐143‐p3, miR‐196b, and miR‐223) in leukemia. It has been shown that deregulation of these molecules are associated with the initiation and progression of leukemia. Hence, miRNAs could be used as potential therapeutic candidates in the treatment of patients with leukemia. Moreover, increasing evidence revealed that miRNAs could be used as diagnostic and prognostic biomarkers in monitoring patients in early stages of disease or after received chemotherapy regimen. It seems that identification and development of new miRNAs could pave to the way to the development new therapeutic platforms for patients with leukemia. Here, we summarized various miRNAs as tumor suppressor and oncogene which could be introduced as therapeutic targets in treatment of leukemia.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0021-9541 1097-4652
DOI:	10.1002/jcp.27776